Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22578585 | 0.87 | F2 (0.35) | NOS1MEN1NOS3KMT2ATDP1 | |
| SCHEMBL14220423 | 0.82 | LMNA (0.39) | KMT2AF2LMNA | |
| SCHEMBL28377793 | 0.82 | LMNA (0.39) | KMT2AF2LMNA | |
| SCHEMBL22578660 | 0.80 | F2 (0.36) | F2LMNA | |
| SCHEMBL17234482 | 0.79 | LMNA (0.38) | MEN1KMT2AF2LMNAALDH1A1 | |
| SCHEMBL13154173 | 0.79 | GRIN2D (0.52) | MEN1KMT2AF2LMNAALDH1A1 | |
| SCHEMBL3129345 | 0.78 | NOS1 (0.59) | NOS1MEN1NOS3KMT2ATDP1 | |
| SCHEMBL13312926 | 0.77 | DDAH1 (0.46) | MEN1KMT2AF2LMNAALDH1A1 | |
| SCHEMBL14344842 | 0.77 | — | — | |
| SCHEMBL21597311 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | OTAGO INNOVATION LIMITED (NZ) | 2023-07-04 | — | — | US | disclosed |
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | OTAGO INNOVATION LIMITED (NZ) | 2023-07-04 | — | — | US | disclosed |
| US-20200385354-A1 | Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents | OTAGO INNOVATION LIMITED (NZ) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | NQO2, SDHA, SIRT5 | NOS1 1814/4885MEN1 4440/4885NOS3 1883/4885 |
| US-20200385354-A1 | Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents | NQO2, SDHA, SIRT5 | NOS1 1814/4885MEN1 4440/4885NOS3 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.